鈴木 憲史 先生のプロフィール

鈴木 憲史 先生

すずき けんし

鈴木 憲史 先生

日本赤十字社医療センター 骨髄腫アミロイドーシスセンター長/薬剤部長/輸血部長/教育研修推進室長/治験センター長

専門分野

血液腫瘍(白血病、リンパ腫、骨髄腫)、貧血、出血傾向の治療、造血幹細胞移植

紹介

日本赤十字社医療センター骨髄腫アミロイドーシスセンターにてセンター長を務める。難治性の高いアミロイドーシスの患者さんであってもトリアージをせず、「全ての患者さんに治療を試みる」ことをモットーとしており、患者さんとご家族から厚い信頼を得ている。ALアミロイドーシス患者の会の顧問医師を務めるなど、病気に対する不安を取り除くための活動にも尽力している。

略歴

1976年 国立新潟大学医学部卒業
1976年 日本赤十字社医療センター内科研修医
1978年 日本赤十字社医療センター内科医師
1990年 日本赤十字社医療センター第2内科副部長
1995年 日本赤十字社医療センター第2内科(血液)部長
2012年 日本赤十字社医療センター副院長 (平成28年定年)
2014年 日本赤十字社医療センター薬剤部長兼務
2016年 日本赤十字社医療センター骨髄腫アミロイドーシスセンターセンター長・薬剤部長・輸血部長

所属学会・資格・役職など

医学博士
日本内科学会内科指導医・総合内科専門医・評議員
日本内科学会専門医部会評議員
日本血液学会指導医・血液専門医・代議員
日本医師会認定産業医
昭和大学客員教授
日本骨髄腫学会理事―功労会員
日本免疫治療学研究会理事
臨床研修指導医
レブメイト第3者評価委員会委員長、厚労省医薬品安全対策調査会参考人、ベルケイド運営委員会委員、東京都医師会生涯教育委員会委員, 厚労科研主任研究員

受賞・著書・論文など

【英文論文】
1) Y.Eishi, K.Suzuki, S.Hatakeyama . Freeze-Preservation of staining solutions in enzyme histochemistry. Bull Tokyo Med and Dent Univ 29;47-52, 1982.
2) K.Suzuki, K.Hirokawa, S.Hatakeyama. Age-related change of distribution of immunoglobulin containing cells in human bone marrow –Changes in patients with benign monoclonal gammopathy and multiple myeloma Virchows Arch(Pathol Anat)404;243-251,1984. 【学位主論文】
3) K.Suzuki, T.Takemura, R.Okeda, S.Hatakeyama. Vascular changes of Methotrexate-related disseminated necrotizingLeukoencephalogy  Acta Neuropathol (Berl)65;145-149, 1984.【学位副論文】
4

【英文論文】
1) Y.Eishi, K.Suzuki, S.Hatakeyama . Freeze-Preservation of staining solutions in enzyme histochemistry. Bull Tokyo Med and Dent Univ 29;47-52, 1982.
2) K.Suzuki, K.Hirokawa, S.Hatakeyama. Age-related change of distribution of immunoglobulin containing cells in human bone marrow –Changes in patients with benign monoclonal gammopathy and multiple myeloma Virchows Arch(Pathol Anat)404;243-251,1984. 【学位主論文】
3) K.Suzuki, T.Takemura, R.Okeda, S.Hatakeyama. Vascular changes of Methotrexate-related disseminated necrotizingLeukoencephalogy  Acta Neuropathol (Berl)65;145-149, 1984.【学位副論文】
4) T.Furukawa, K.Suzuki. et al. A case of aneurysm of the jugular and mediastinal veins-radioisotopic blood pool study of venous aneurysm- Eur J Nucl Med 9;196-198, 1984.
5) M.Tanaka, K.Suzuki. et al. Cardiovascular lesion of carcinoid syndrome. An autopsy case of brochial Carcinoid. Acta Pathol Jpn 34;201-213, 1984.
6) K.Suzuki, K.Hirokawa, R.Kamiyama, S.Hatakeyama. Distribution of immunoglobulin containing cells in human bone marrow of patients with leukemia Acta Pathol Jpn 37; 193-199, 1987.
7) K.Suzuki, K.Hirokawa, T.Takemura, Y.Esaki. Age-related change in the number of mast cells in human bone marrow and spleen Acta Haematol Jpn 51;739-745, 1988.
8) K.Suzuki, T.Hosoi, A.Urabe, F.Takaku. In Vitro immunoglobulin production in mitgen-stimulated cultures of peripheral blood and bone marrow cells from young and old adults,and cases of benign monoclonal gammopathy Acta Haematol Jpn 52;756-762, 1989
9) K.Suzuki, A Miyashita. et al. Interleukin-6-producing pheochromocytoma Acta Haematol 85;217-219, 1991.
10) M.Usuyama, K.Suzuki. et al. Differential age-change in the numbers of CD4+ CD45RA+ and CD4+CD29+ T cell subsets in human peripheral blood Mech Age Develop 63;57-68, 1992.
11) M.Nara, K.Suzuki. et al. A Case of Mulutiple Myeloma with Nuclear Hypersegmentation after MP/VAD/VCAP-IFN Therapies with a Good Prognosis Acta Haematol 90;102-103, 1993
12) S.Hitoshi, K.Suzuki, M.Sakuta. Elevated Serum Interleukin-6 in POEMS Syndrome Reflects the Activity of the Disease Internal Medicine 33;583-587, 1994.
13) J.Tsuchiya, K.Suzuki. et al. Ten-year survaival and prognostic factor in mulutiple myeloma. British Journal of Haematology 87;832-834, 1994
14) K.Suzuki,Y.Aoyagi. et al and The Japanese Cooerative Group on CLL. Clinical investigation of cases of chronic lymphocytic leukemia in Japan Oncology Reports 3;477-482, 1996
15) K.Toyama, K.Suzuki. et al. Effect of recombinant human Granurocyte Colony-Stimulating Factor on combination Therapy with Aztreonam and Clindamycin for infections in neutropenic patients with Hematologic disease. J Infect Chemother 70;1242-1253, 1996
16) S.Iki, K.Suzuki., A.Urabe, et al. Increased neutrophil respiratory burst in myeloproliferative disorders: Selective enhancement of superoxide release triggered by receptor-mediated Agonists and low responsiveness to in vitro cytokine stimulation Exp.Haematol 25;26-33, 1997
17) M.Sawanobori, K.Suzuki. et al. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis Acta Haematol 98;150-154, 1997
18) M.Shiba,K.Suzuki. et al. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. TRANSFUSION 37;457-462, 1997
19) M.Sawanobori, K.Suzuki. et al. Sever thrombocytopenia after cytomegalovirus infection in an immunocompetent host -Correlation between CMV infection and platelet count in immunocompetent hosts- Japanese Journal of Clinical Immunology 20;134-138, 1997
20) M.Nieda, K.Suzuki. et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+T cells with cytotoxic activity aganst leukemic cells form patients with chronic myeloid leukemia. Blood 91;977-983, 1998
21) A Nicol, M.Nieda, K.Suzuki. et al. Dendritic cells are targets for human invariant Va24+ natural killer T-cell cytotoxic activity: An important immune regulatory function Exp Hematol 28:276-282,2000
22) A Nicol, M.Nieda, K.Suzuki. et al. Human invariant Va24+ natural killer T cells activated by a-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms direct from T cells and natural killer cells Immunology 99:229-234,2000
23)M.Nieda, A Nicol, K.Suzuki. et al. TRAIL expression by activated human CD4+ Va24NK T-cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood97:2067-2073,2001
24)M.Mori,Y.Nakagawa, K.Suzuki. et al. Reduced-dose CHOP therapy for elderly patients with non-hodgkins lymphoma. Leukemia and Lymphoma41:359-366,2001 
25)K. Ishiyama, M. Sawanobori, S. Nakao et al. Aplastic anemia with 13q-: a benign subset of bone marrow failure responsive to immunosuppressive therapy. Br J Haematol 117:747-750, 2002
26) S. Turumi, K. Suzuki, K. Mitani et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol 71:131-133,2002
27)Y Nakagawa, M Sawanobori, H Amaya, I Matuda, Y Inoue, S Hashimoto, K Kannno,
K Suzuki . Clinical implications of abnormalities of chromosomes 1 and 13 in multiple myeloma. Acta Haematol 109:129-136,2003
28)Sawanobori M, Yamaguchi S, Suzuki K, Kitagawa M: Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leukemia Research 27:583-591,2003
29)Asano(Mori) Y, Kanda Y, et al: Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 32:1175-1179,2003.
30)Nakagawa Y, Suzuki K, et al. Differential exporession of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
Leukemia Research 28 :487-494,2004.
31) Yamamoto K, Nakagawa Y, Suzuki K, et al. Expression of IAP family proteins in myelodysplastic sydromes transforming to overt leukemia. Leukemia Research 28:l203-1211,2004.
32) Tamura K, Suzuki K, Masaoka K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacine as empirical therapy for febrile neutropenia. Clin Infec Diseases 39:15-24,2004.
33) Suzuki K. Light- and heavy-chain deposition desease(LHCDD): difficulty in diagnosis and treatment. Intern Med 44:915-916, 2005.
34) Suzuki K. Stem cell transplantation for multiple myeloma. The 3rd annual meeting of asian hematology association p23-24,2005.
35)Y Nakagawa, M Hasegawa, K Suzuki, and M Kitagawa. Expression of IAP-Family Proteins in Adult Acute Mixed Lineage Leukemia (AMLL) American Journal of Hematology 78:173–180 (2005)
36)Y Nakagawa, S Abe, K Suzuki, and M Kitagawa. IAP family protein expression correlates with poor outcome of multiple myelomapatients in association with chemotherapy-induced over expression of multidrug resistance genes. American Journal of Hematology 81:824–831 (2006)
37)Y Nakagawa, Yoko Ichii,, K Suzuki, S Kisino. J Plasma concentration of micafungin in patients with hematologic malignancies.
Infect Chemother 13:39-45(2007)
38)S Abe, Maki Hasegawa, Y Nakagawa, K Suzuki, T Takizawa, M Kitagawa. Rapid induction of IAP family proteins and Smac/DIABLO expression after proapoptotic stimulation with doxorubicin in RPMI 8226 multiple myeloma cells.
Exp Molecular Path x(2007)
39)T Keith,Y Araki, Mi Ohyagi,,Y Nakagawa, K Suzuki, M Kitagawa. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 137:206-215 (2007)
40) J Shiraisi, K Suzuki, T takemura et al. Type AB thymoma accompanied by pure red cell aplasia and good syndrome with CMV infection of tumor cells  Pathology International 58:489-493,2008
41)J Shiraisi, Y Nakagawa, K Suzuki, M Kitagawa, T takemura et al. Follicular lymphoma with marked infiltration of eosinophils Pathology International 58:701-705, 2008
42)Y Nakagawa, Y Ichii, K Suzuki et al . Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies. Eur. J. Drug Metab Pharmacokinet 33:191-198,2008
43)Y Abe, Y Nakagawa, K Suzuki et al. Clinical and immunological evaluation of zoledronate-activated V9 T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956-968, 2009
44)Y Nakagawa, K Suzuki, T Masaoka. Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174-179, 2009
45)H Murakami, Ki Shimizu,, K Suzuki et al. Phase Ⅱ and pharmacokinetic study of tthalidomide in Japanese patients with relapsed/refractory multiple myeloma Int J Hematol 89:636-641, 2009
46)K Azakami, T Sato, K Suzuki et a. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders
l Blood 114: 3208-3215, 2009
47)H Harada, M Watanabe, K Suzuki et al. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. Int J Hematol 90:353-360,2009
48) N Kuniaka, Y Nakagawa, K Suzuki, M Kitagawa et al. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes in down-egulated during transformation to overt leukemia. Exp. Molecul. Path. 88:293-298, 2010
49) Smith TJ, Y Nakagawa, K Suzuki, M Kitagawa et al.Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp. Mol. Pathol.2010 【Pub Med】
50) Y Nakagawa, K Suzuki, A Urabe et al. Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.  J Infect Chemother 17:58-67, 2011
51)Nicol AJ, H Tokuyama, K Suzuki., M Nieda et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer105:778-786, 2011
52)S Yoshizawa, JH Ohyashiki, M Ohyashiki, T Umezu, K Suzuki. A Inagaki, S Iida and K Ohyashiki:. Down regulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer Journal (2012) 2, e53, published online 20 Jan. 2012
53)K Suzuki: Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol. 16:659-671, 2012
54) K Suzuki: Current therapeutic strategy for Multiple myeloma. Jpn J Clin Oncol 43:116-124, 2013
55) K Suzuki: Diagnosis and Treatment of Multiple Myeloma and AL Amyloidosis with Focus on Improvement of Renal Lesion 6thAnnual World Cancer Congress-2013 Xian ,China 23/May/2013
56) Ogawa Y, Suzuki K, Hotta T et al: Phase 1/2 study of bortezomib  -melphalan- Prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Science, doi:10.1111/cas.12172,2013
57)Nakagawa Y, K Suzuki., Masaoka T et al: Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neiutropenia. J Infect Chemother 19:103-111,2013.
58)Ozaki S, Harada T, Saitou T, Suzuki K et al: Survival of multiple myeloma patients aged 65-70 years in the Era of novel agents aqnd autologous stem cell transplantation. Acta Hematol. 132:211-219,2014
59) Kim K, Lee H, Kim JS, Suzuki K, et al: Clinical profiles of multiple myeloma in Asia-An Asian myeloma network study. Am J Hematol 89:751-756, 2014
60) Miyazaki K, Suzuki K: Unusual intracytoplasmic crystalline inclusions in chronic myelomonocytic leukemia with double minute chromosomes and MYC amplification: A rare case. Acta Hematol 132:68-72,2014
61) Handa H, Suzuki K, Chou T, et al. Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide–Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2014; 124, 5752 
62) K Suzuki, M Ogura, Y Abe, A phase 1 study of siltuximab, an anti-IL-6 mAb, in relapsed/refractory multiple myeloma. Int J Hematol 2015 Mar;101(3):286-94 
63) Miyazaki K, Suzuki K: Clinical and laboratory significance of CD56 (a neural cell adhesion molecule) positivity in multiple myeloma and AL amyloidosis Int J Myel 5(3): 30–35, 2015
64) K Miyazaki, S Kawai, K Suzuki: Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry. Int J Hematol 102:289-295,2015
65) J Inoue, M Ikeda, K Suzuki, et.al: The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma. Rinshou ketueki 56:2311-2317,2015
66) T Watanabe, K Suzuki, S Iida:A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol doi: 10.1111
/bjh.13900.2016
67) C Shimazaki, S Fuchida, K Suzuki et al: Phase 1 Study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL Amylopidosis. Int J Hematol 103:79-85,2016
68) Suzuki K, et al Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study. Cancer Sci. 2016 Feb 23.
69) Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y.: Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. Int J Hematol. 2016 Jan;103(1):79-85.
70)Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y, Abe Y, Suzuki K.
:High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. Int J Hematol. 2016 Mar;103(3):299-305.
71) Ichinohe T, Kuroda Y, Suzuki K. et al. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol 2016.5:11 Doi 10.1186.
72) Suzuki K1, Masaki Ri2, Takaaki Chou3, Isamu Sugiura4, Naoki Takezako5, Kazutaka Sunami6, Tadao Ishida7, Tohru Izumi8, Shuji Ozaki9, Yoshihisa Shumiya10, Kenji Ota10, Shinsuke Iida2 Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma: A multicentre, open-label, phase 1 study in Japan (in press)
73) Meletios A. Dimopoulos,1 Albert Oriol,2 Hareth Nahi,3 Jesus San Miguel,4 Nizar J. Bahlis,5 Neil Rabin,6 Robert Z. Orlowski,7 Mieczyslaw Komarnicki,8 Suzuki K.,9 Torben Plesner,10 Olga S. Samoilova,11 Sung-Soo Yoon,12 Dina Ben Yehuda,13 Paul G. Richardson,14 Hartmut Goldschmidt,15 Donna Reece,16 Nushmia Khokhar,17 Lisa O’Rourke,17 Christopher Chiu,17 Xiang Qin,17 Mary Guckert,17 Tahamtan Ahmadi,17 Philippe Moreau18 An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX EHA2016 (in press)
74) Suzuki K,1 Hiroshi Handa,2 Takaaki Chou,3 Kenichi Ishizawa,4 Takatoshi Takubo,5 Yoichi Kase6 A Phase 1 Study of Ixazomib Alone or Combined with Lenalidomide- Dexamethasone in Japanese Patients with Relapsed/Refractory Multiple Myeloma (in press)

続きを見る

鈴木 憲史先生 の所属する医療機関

日本赤十字社医療センター

TEL: 03-3400-1311

日本赤十字社医療センター

東京都渋谷区広尾4丁目1-22

東京メトロ日比谷線「広尾」駅 徒歩15分

JR山手線「渋谷」駅 東口 都バス 学03系統 日赤医療センター行 終点下車すぐ バス15分

- - -

診療時間: 8:30〜15:00 原則紹介制、一部診療科予約制 AM受付は11:00まで、以降はPM診察となる 診療時間は原則として9:00〜12:00 13:00〜終了まで 科により異なる 創立記念日(5/1)休診 臨時休診あり

診療科目: 内科 アレルギー科 血液内科 リウマチ科 外科 精神科 神経内科 脳神経外科 呼吸器外科 消化器外科 腎臓内科 心臓血管外科 小児科 小児外科 整形外科 皮膚科 泌尿器科 産婦人科 眼科 耳鼻咽喉科 リハビリテーション科 放射線科 歯科口腔外科 麻酔科 乳腺外科

鈴木 憲史 先生 の記事